Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$6.20 +2.3%	$4.68	$3.21 ▼ $7.18	$1.46B	0.68	4.68 million shs	1.79 million shs
AXSM Axsome Therapeutics	$121.15 +4.2%	$107.04	$75.56 ▼ $139.13	$5.80B	0.51	585,898 shs	547,162 shs
CRSP CRISPR Therapeutics	$54.88 +1.4%	$55.23	$30.04 ▼ $71.13	$4.92B	1.8	2.93 million shs	1.28 million shs
NUVL Nuvalent	$74.93 +1.2%	$78.49	$55.53 ▼ $113.51	$5.34B	1.3	437,023 shs	359,402 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-0.82%	+4.30%	+41.26%	+52.64%	-4.57%
AXSM Axsome Therapeutics	-1.86%	+4.66%	+15.35%	+11.86%	+32.19%
CRSP CRISPR Therapeutics	-0.35%	-6.01%	-16.41%	+44.08%	+11.17%
NUVL Nuvalent	-2.67%	-1.28%	-9.04%	+2.46%	-13.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.2713 of 5 stars	3.5	2.0	4.4	2.8	2.5	0.6
AXSM Axsome Therapeutics	4.8215 of 5 stars	4.5	1.0	4.5	4.1	4.2	0.6
CRSP CRISPR Therapeutics	3.6343 of 5 stars	4.3	3.0	0.0	2.2	3.3	0.6
NUVL Nuvalent	3.3617 of 5 stars	4.5	1.0	0.0	3.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$11.50	85.48% Upside
AXSM Axsome Therapeutics	3.07	Buy	$178.00	46.93% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	30.47% Upside
NUVL Nuvalent	3.08	Buy	$118.91	58.69% Upside

Current Analyst Ratings Breakdown

Latest ARDX, NUVL, AXSM, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	NUVL Nuvalent	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$112.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	ARDX Ardelyx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
8/5/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00
8/5/2025	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $14.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.61M	4.48	N/A	N/A	$0.73 per share	8.49
AXSM Axsome Therapeutics	$385.69M	15.67	N/A	N/A	$1.18 per share	102.67
CRSP CRISPR Therapeutics	$37.31M	133.78	N/A	N/A	$22.64 per share	2.42
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.23	N/A	20.00	N/A	-14.60%	-36.57%	-13.42%	10/30/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	42.96	N/A	-49.88%	-283.22%	-33.06%	11/11/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	11/11/2025 (Estimated)

Latest ARDX, NUVL, AXSM, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/4/2025	Q2 2025	ARDX Ardelyx	-$0.13	-$0.08	+$0.05	-$0.08	$82.69 million	$97.66 million
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.44	4.30	4.03
AXSM Axsome Therapeutics	1.66	1.57	1.51
CRSP CRISPR Therapeutics	N/A	16.61	16.61
NUVL Nuvalent	N/A	13.57	13.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
AXSM Axsome Therapeutics	81.49%
CRSP CRISPR Therapeutics	69.20%
NUVL Nuvalent	97.26%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
AXSM Axsome Therapeutics	22.40%
CRSP CRISPR Therapeutics	4.10%
NUVL Nuvalent	10.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	240.98 million	229.42 million	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.72 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.22 million	Optionable
NUVL Nuvalent	40	72.11 million	64.75 million	Optionable

ARDX, NUVL, AXSM, and CRSP Headlines

Recent News About These Companies

T. Rowe Price Investment Management Inc. Makes New $31.97 Million Investment in Nuvalent, Inc. $NUVL

August 26 at 4:49 AM | marketbeat.com

Nuvalent, Inc. $NUVL Shares Purchased by American Century Companies Inc.

August 26 at 3:50 AM | marketbeat.com

Nuvalent, Inc. $NUVL Shares Purchased by Wellington Management Group LLP

August 24 at 5:15 AM | marketbeat.com

Nuvalent, Inc. $NUVL Shares Sold by Deutsche Bank AG

August 24 at 3:28 AM | marketbeat.com

Nuvalent, Inc. $NUVL Shares Sold by Charles Schwab Investment Management Inc.

August 24 at 3:18 AM | marketbeat.com

Candriam S.C.A. Sells 13,966 Shares of Nuvalent, Inc. $NUVL

August 23 at 7:05 AM | marketbeat.com

Aberdeen Group plc Acquires 19,987 Shares of Nuvalent, Inc. $NUVL

August 23 at 4:34 AM | marketbeat.com

Nuvalent, Inc. $NUVL Shares Purchased by Russell Investments Group Ltd.

August 22, 2025 | marketbeat.com

Nuvalent (NASDAQ:NUVL) CEO Sells $2,036,340.00 in Stock

August 21, 2025 | marketbeat.com

Nuvalent (NASDAQ:NUVL) Now Covered by Piper Sandler

August 21, 2025 | marketbeat.com

Insider Selling: Nuvalent (NASDAQ:NUVL) CEO Sells 27,000 Shares of Stock

August 20, 2025 | insidertrades.com

Piper Sandler Initiates Coverage on Nuvalent (NASDAQ:NUVL)

August 20, 2025 | americanbankingnews.com

Piper Sandler Initiates Coverage of Nuvalent (NUVL) with Overweight Recommendation

August 19, 2025 | msn.com

Nuvalent initiated with an Overweight at Piper Sandler

August 19, 2025 | msn.com

Vanguard Group Inc. Decreases Holdings in Nuvalent, Inc. $NUVL

August 19, 2025 | marketbeat.com

Lord Abbett & CO. LLC Sells 112,621 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 18, 2025 | marketbeat.com

Citigroup Inc. Purchases 112,519 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 15, 2025 | marketbeat.com

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

August 13, 2025 | prnewswire.com

Wedbush Forecasts Nuvalent's Q3 Earnings (NASDAQ:NUVL)

August 11, 2025 | marketbeat.com

Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock

August 10, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Insider Henry E. Pelish Sells 5,500 Shares

August 9, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX, NUVL, AXSM, and CRSP Company Descriptions

Ardelyx NASDAQ:ARDX

$6.20 +0.14 (+2.31%)

Closing price 04:00 PM Eastern

Extended Trading

$6.17 -0.03 (-0.48%)

As of 07:42 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Axsome Therapeutics NASDAQ:AXSM

$121.15 +4.84 (+4.16%)

Closing price 04:00 PM Eastern

Extended Trading

$121.15 0.00 (0.00%)

As of 07:57 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CRISPR Therapeutics NASDAQ:CRSP

$54.88 +0.75 (+1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$54.90 +0.02 (+0.04%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Nuvalent NASDAQ:NUVL

$74.93 +0.88 (+1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$74.95 +0.02 (+0.03%)

As of 04:34 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time